Ophthalmic results in patients with macroprolactinomas treated with a new prolactin inhibitor CV 205-502.
Grochowicki M, Khalfallah Y, Vighetto A, Berquet S, Sassolas G
AI Summary
This study found the prolactin inhibitor CV 205-502 effectively improved or stabilized visual function in macroprolactinoma patients, demonstrating its clinical utility in preserving vision affected by these tumors.
Abstract
Macroprolactinomas are pituitary tumours which have been effectively treated medically since the introduction of bromocriptine. The visual function of 13 patients treated with a new prolactin (PRL) inhibitor CV 205-502 (Sandoz Basle), a potent and selective dopamine D2 receptor agonist, was evaluated. This is the first detailed ophthalmic report of the use of this drug in macroprolactinomas. Patients were enrolled from June 1988 to July 1990 (mean follow up 30 months). Visual function including visual acuity, ocular pressure, and visual fields was regularly controlled. Visual fields (VF) were tested with Goldmann and automatic static perimetry (Vision Monitor). Treatment was globally effective. No modifications of the visual function were observed in nine patients (six normal, three previous VF losses after surgery). In four other patients, visual function dramatically improved (regression of a III paresis, one case; disappearance of a chiasmatic syndrome, three cases). A pituitary necrosis was observed in one case and successfully cured. CV 205-502 seems to be an effective and well tolerated treatment of macroprolactinomas.
MeSH Terms
Shields Classification
Related Articles5
Does the Visual Field Improve After Initiation of Intraocular Pressure Lowering in the United Kingdom Glaucoma Treatment Study?
Randomized Controlled TrialThe Glaucoma Intensive Treatment Study (GITS): A Randomized Controlled Trial Comparing Intensive and Standard Treatment on 5 Years Visual Field Development.
Randomized Controlled TrialThe effect of long-term intraocular pressure reduction on the differential light sensitivity in glaucoma suspects.
Cohort StudyLongterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma.
Randomized Controlled TrialChanges in visual function after intraocular pressure reduction using antiglaucoma medications.
Randomized Controlled TrialIs this article assigned to the wrong chapter(s)? Let us know.